Viking Therapeutics, Inc. (VKTX) Return on equity 2016–2025
Viking Therapeutics, Inc. (VKTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-56.3%FY2025 · since FY2016: -183.2% → -56.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -56.3% | -43.8 pp |
| FY2024 | -12.5% | +12.2 pp |
| FY2023 | -24.7% | +22.7 pp |
| FY2022 | -47.4% | -20.2 pp |
| FY2021 | -27.2% | -11.1 pp |
| FY2020 | -16.2% | -6.9 pp |
| FY2019 | -9.3% | -1.9 pp |
| FY2018 | -7.4% | +145.4 pp |
| FY2017 | -152.8% | +30.3 pp |
| FY2016 | -183.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice